SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 354.86 |
| Enterprise Value ($M) | 91.32 |
| Book Value ($M) | 98.02 |
| Book Value / Share | 1.20 |
| Price / Book | 3.62 |
| NCAV ($M) | 39.14 |
| NCAV / Share | 0.48 |
| Price / NCAV | 9.07 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.84 |
| Return on Assets (ROA) | -0.32 |
| Return on Equity (ROE) | -0.62 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.85 |
| Current Ratio | 2.85 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 344.52 |
| Assets | 403.40 |
| Liabilities | 305.38 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 153.73 |
| Operating Income | -89.28 |
| Net Income | -106.79 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -111.62 |
| Cash from Investing | -3.92 |
| Cash from Financing | 137.55 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Point72 Asset Management, L.P. | 7.90 | ||
| 13G/A | Suvretta Capital Management, Llc | 9.50 | 3.83 | |
| 13G/A | Rubric Capital Management LP | 5.49 | 4.14 | |
| 13G/A | Adage Capital Partners Gp, L.l.c. | 7.33 | 25.88 | |
| 13G/A | BlackRock Inc. | 9.60 | 19.83 | |
| 13G | Integrated Core Strategies (us) Llc | 5.70 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| w, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 55,577 | 532,176 | 10.44 | |
| 57,850 | 471,125 | 12.28 | |
| 35,241 | 476,336 | 7.40 | |
| 45,771 | 117,590 | 38.92 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| SMMT – Summit Therapeutics Inc. | SNSE – Sensei Biotherapeutics, Inc. |
| SPRY – ARS Pharmaceuticals, Inc. | SUPN – Supernus Pharmaceuticals, Inc. |
| TARA – Protara Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io